Crystalys Therapeutics Raises $130 Million in Series B Funding
Crystalys Therapeutics, a biotechnology company based in San Diego, California, has announced that it has raised $130 million in its Series B funding round. The round was led by Frazier Life Sciences and included participation from a diverse group of investors including Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, and several others.
Leadership and Vision
The company is spearheaded by co-founders Ashwin Ram, James Mackay, and Nihar Bhakta. Ashwin Ram serves as the Chief Operating Officer, James Mackay is the President and CEO, and Nihar Bhakta holds the position of Chief Medical Officer. Together, they lead Crystalys Therapeutics in its mission to advance innovative therapies for unmet medical needs.
Lead Investor: Frazier Life Sciences
Frazier Life Sciences, known for its focus on investing in life science companies with transformative potential, took the lead in this funding round. This involvement highlights the confidence investors have in Crystalys Therapeutics' approach and potential impact in the biotechnology sector.
Participation from a Wide Range of Investors
In addition to Frazier Life Sciences, the Series B funding round saw a wide array of investors. These include Wellington Management, HBM Healthcare Investments, Soleus Capital, Cormorant Asset Management, Trails Edge Capital Partners, Pivotal bioVenture Partners, KCap Biotechnology Fund, Novo Holdings, SR One, Catalys Pacific, Perceptive Xontogeny Venture Funds, Lightstone Ventures, AN Venture Partners, KB Investments, Pontifax, Longwood Fund, Alexandria Venture Investments, Wedbush Healthcare Partners, and Prebys Ventures Fund.
Planned Use of Funds
While specific details on the allocation of the funds were not disclosed, companies in similar stages typically use such investments to enhance their research and development capabilities, expand their teams, and accelerate clinical trials. With this significant financial boost, Crystalys Therapeutics is well-positioned to further its therapeutic platform and bring new treatments to market.
Conclusion
This substantial Series B funding round marks a significant milestone for Crystalys Therapeutics, underscoring the biotech company's potential to make impactful advancements in the field of medical treatments. With strong backing from a mix of strategic investors, the company is poised to continue its development and growth in the biotechnology industry.